Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis - 07/01/23
Hightlights |
• | This is a meta-analysis comparing the efficacy and safety of lenvatinib and sorafenib for patients with advanced HCC in the real world. |
• | Significant better overall survival and progress-free survival rates were investigated in those patients who received lenvatinib. |
• | The incidences of AEs were higher in patients receiving lenvatinib than those receiving sorafenib. |
Abstract |
Background and aim |
The first-line systemic therapy for advanced hepatocellular carcinoma (HCC) involves the use of sorafenib and lenvatinib. The present meta-analysis attempted to compare the therapeutic safety and effectiveness of the two drugs in advanced HCC.
Methods |
The library databases of Cochrane, Embase, PubMed, and Web of Science were systematically searched to identify eligible studies comparing the long-term outcomes of sorafenib and lenvatinib use in advanced HCC patients. Overall survival (OS) was considered the primary endpoint, whereas the progression-free survival (PFS), severe adverse events (AEs), objective response rate (ORR), and disease control rate (DCR) were considered the secondary endpoints.
Results |
The present systematic review included 8 nonrandomized studies and 1 randomized controlled trial, comprising a total of 1, 914 cases. OS in patients receiving lenvatinib was better than that in patients receiving sorafenib [hazard ratio (HR): 1.23; 95% confidence interval (CI): 1.04–1.45]. Additionally, patients who received lenvatinib exhibited better PFS, ORR, and DCR (HR: 0.89, 95% CI: 0.79–0.99), [odds ratio (OR: 7.50, 95% CI: 4.43–12.69)], (OR: 7.50, 95% CI: 4.43–12.69), but higher incidences of AEs than those receiving sorafenib (OR: 1.28, 95% CI: 1.08–1.53).
Conclusion |
Lenvatinib is superior to sorafenib in treating unresectable HCC patients.
Le texte complet de cet article est disponible en PDF.Keywords : Sorafenib, Lenvatinib, Hepatocellular carcinoma, Unresectable, Advanced, Meta-analysis
Abbreviations : HCC, BCLC, EASL, AASLD, TKI, SHARP, OS, PFS, ORR, RCT, NOS, AE, DCR, mRECIST, HR, CI, HBV, HCV, ECOG, MVI, EHS, AFP
Plan
Vol 47 - N° 1
Article 102061- janvier 2023 Retour au numéro
Article précédent
- Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/hepatitis B - induced hepatic injury
- Feng Chen, Yingxia Liu, Qianhui Li, Fei Wang
- Macrophages and derived-TNF-α promote lipopolysaccharide-induced upregulation of endogenous β-glucuronidase in the epithelial cells of the bile duct: A possible facilitator of hepatolithiasis formation
- Ye Yang, Yang Wang, Cuifang Wang, Shuodong Wu, Dianbo Yao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?